Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by B. Reix.
Urologic Oncology-seminars and Original Investigations | 2017
Pierre Bigot; Jean-Christophe Bernhard; Vincent Flamand; Inderbir S. Gill; G. Verhoest; Jean Baptiste Beauval; François Xavier Nouhaud; Evren Süer; G. Ploussard; Jean François Hetet; J. Rigaud; Eduard Baco; S. Larré; Philippe Sebe; Nicolas Koutlidis; Aurélien Descazeaud; Masatoshi Eto; Arnaud Doerfler; Morgan Rouprêt; Nam Son Vuong; B. Reix; Toru Matsugasumi; Adnan El Bakri; Laurence Albiges; Michel Soulie; Jean-Jacques Patard; Arnaud Mejean; Karim Bensalah
OBJECTIVE To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). MATERIAL AND METHODS We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed. RESULTS We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. CONCLUSION Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
Progres En Urologie | 2018
B. Reix; Jean Christophe Bernhard; Jean Jacques Patard; Pierre Bigot; A Villers; Evren Süer; Nam Son Vuong; G. Verhoest; Q. Alimi; Jean Baptiste Beauval; T. Benoit; François Xavier Nouhaud; C. Lenormand; N Hamidi; J Cai; Masatoshi Eto; Stéphane Larré; A El Bakhri; Guillaume Ploussard; A Hung; Nicolas Koutlidis; A. Schneider; J Carrouget; S. Droupy; S Marchal; Arnaud Doerfler; S Seddik; Toru Matsugasumi; X Orsoni; A Descazeaud
BACKGROUND Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. METHOD A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR). We considered all patients aged≥18 years who underwent surgical treatment for localized renal cell carcinoma (RCC) stage cT2a (7.1-10cm) between 2000 and 2014. Cox and Fine-Gray models were performed to analyze overall survival (OS), cancer specific survival (CSS) and cancer-free survival (CFS). Comparison between PN and RN was realized after an adjustment by propensity score considering predefined confounding factors: age, sex, tumor size, pT stage of the TNM classification, histological type, ISUP grade, ASA score. RESULTS A total of 267 patients were included. OS at 3 and 5 years was 93.6% and 78.7% after PN and 88.0% and 76.2% after RN, respectively. CSS at 3 and 5 years was 95.4% and 80.2% after PN and 91.0% and 85.0% after RN. No significant difference between groups was found after propensity score adjustment for OS (HR 0.87, 95% CI: 0.37-2.05, P=0.75), CSS (HR 0.52, 95% CI: 0.18-1.54, P=0.24) and CFS (HR 1.02, 95% CI: 0.50-2.09, P=0.96). CONCLUSION PN seems equivalent to RN for OS, CSS and CFS in cT2a stage kidney tumors. The risk of recurrence is probably more related to prognostic factors than the surgical technique. The decision to perform a PN should depend on technical feasibility rather than tumor size, both to imperative and elective situation. LEVEL OF EVIDENCE 4.
World Journal of Urology | 2016
Pierre Bigot; Jean Christophe Bernhard; Inderbir S. Gill; Nam Son Vuong; G. Verhoest; Vincent Flamand; B. Reix; Evren Süer; İlker Gökçe; Jean Baptiste Beauval; François Xavier Nouhaud; Masatoshi Eto; Eduard Baco; Toru Matsugasumi; Yvonne Chowaniec; J. Rigaud; C. Lenormand; C. Pfister; Jean François Hetet; G. Ploussard; Morgan Rouprêt; Priscilla Léon; Adnan El Bakri; S. Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeaud; Nicolas Koutlidis; A. Schneider; Philippe Sebe
European Urology Supplements | 2015
J-C. Bernhard; J.J. Patard; Pierre Bigot; Evren Süer; N. Vuong; G. Verhoest; Q. Alimi; Vincent Flamand; B. Reix; J-B. Beauval; T. Benoit; F. Nouhaud; C. Lenormand; N. Hamidi; A. Hung; J. Cai; Masatoshi Eto; S. Larré; A. El Bakri; Eduard Baco; G. Ploussard; Nicolas Koutlidis; A. Schneider; Morgan Rouprêt; Priscilla Léon; J. Carrouget; S. Droupy; S. Marchal; Arnaud Doerfler; S. Seddik
The Journal of Urology | 2015
Pierre Bigot; Jean Christophe Bernhard; Inderbir S. Gill; G. Verhoest; B. Reix; Evren Süer; Masatoshi Eto; François Xavier Nouhaud; Vincent Flammand; İlker Gökçe; Toru Matsugasumi; Jean Baptiste Beauval; C. Lenormand; Yvonne Chowaniec; J. Rigaud; Christian Pfister; Jean François Hetet; Guillaume Ploussard; Nam Son Vuong; Eduard Baco; Morgan Rouprêt; Priscilla Léon; Adnan El Bakhri; Stéphane Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeau; Philippe Sebe; Nicolas Koutlidis; A. Schneider
The Journal of Urology | 2015
Pierre Bigot; Jean Christophe Bernhard; Inderbir S. Gill; G. Verhoest; B. Reix; Evren Süer; Masatoshi Eto; François Xavier Nouhaud; Vincent Flammand; İlker Gökçe; Toru Matsugasumi; Jean Baptiste Beauval; Yvonne Chowaniec; J. Rigaud; C. Lenormand; Christian Pfister; Jean François Hetet; Guillaume Ploussard; Nam Son Vuong; Eduard Baco; Morgan Rouprêt; Priscilla Léon; Adnan El Bakhri; Stéphane Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeau; Philippe Sebe; Nicolas Koutlidis; A. Schneider
Progres En Urologie | 2015
Pierre Bigot; Jean-Christophe Bernhard; Inderbir S. Gill; N. Vuong; G. Verhoest; V. Flammand; B. Reix; Evren Süer; İlker Gökçe; Jean Baptiste Beauval; F. Nouhaud; Masatoshi Eto; Eduard Baco; Toru Matsugasumi; Yvonne Chowaniec; J. Rigaud; C. Lenormand; C. Pfister; Jean François Hetet; G. Ploussard; Morgan Rouprêt; Priscilla Léon; A. El bakri; S. Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeaud
Progres En Urologie | 2015
Pierre Bigot; Jean-Christophe Bernhard; G. Verhoest; V. Flammand; Inderbir S. Gill; Nam Son Vuong; B. Reix; Evren Süer; İlker Gökçe; Jean Baptiste Beauval; F. Nouhaud; Masatoshi Eto; Eduard Baco; Toru Matsugasumi; Yvonne Chowaniec; J. Rigaud; C. Lenormand; C. Pfister; Jean François Hetet; G. Ploussard; Morgan Rouprêt; Priscilla Léon; A. El bakri; S. Larré; Xavier Tillou; Alexandre Ingels; Arnaud Doerfler
Progres En Urologie | 2015
B. Reix; V. Flamand; Jean-Christophe Bernhard; Pierre Bigot; A. Villers
Progres En Urologie | 2015
Jean-Christophe Bernhard; J.J. Patard; Pierre Bigot; Evren Süer; Nam Son Vuong; G. Verhoest; Q. Alimi; Vincent Flamand; B. Reix; Jean Baptiste Beauval; T. Benoit; F. Nouhaud; C. Lenormand; N. Hamidi; Masatoshi Eto; S. Larré; A. El bakri; Eduard Baco; G. Ploussard; Nicolas Koutlidis; A. Schneider; Morgan Rouprêt; Priscilla Léon; J. Carrouget; S. Droupy; S. Marchal